N-803

Drug identity checked against registry records

Also recorded as ALT-803; Anktiva; also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyNCT03853317IBRXPhase 2Terminated2021-09-29Actual
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809IBRXPhase 2Active not recruiting2029-12-31Estimated
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288IBRXPhase 2Recruiting2027-05Estimated
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399IBRXPhase 2Active not recruiting2025-10-13Actual
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366IBRXPhase 2Not yet recruiting2027-12Estimated
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyNCT06745908IBRXPhase 3Recruiting2028-09Estimated
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerNCT03022825IBRXPhase 2, Phase 3Active not recruiting2024-10-01Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.